The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results.
Bartomeu Massuti
No relevant relationships to disclose
Ramon Lecumberri
No relevant relationships to disclose
Guillermo M Lopez Vivanco
No relevant relationships to disclose
Albert Font
No relevant relationships to disclose
Enrique Gonzalez-Billalabeitia
No relevant relationships to disclose
Juan Luis Marti-Ciriquian
No relevant relationships to disclose
Jose Gómez-Codina
No relevant relationships to disclose
Manuel Domine
No relevant relationships to disclose
Isabel Bover
No relevant relationships to disclose
Dolores Isla
No relevant relationships to disclose
Antonio Galan
No relevant relationships to disclose
Alfonso Gurpide
No relevant relationships to disclose
Vicente Vicente
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose
Mayte Monreal
Employment or Leadership Position - Laboratorio Farmaceutico Rovi
Eduardo Rocha
Research Funding - Laboratorios Farmaceuticos Rovi